Skip to Content

Chimerix Inc CMRX

Morningstar Rating
$0.96 +0.01 (1.49%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CMRX is trading at a 63% discount.
Price
$0.95
Fair Value
$1.95
Uncertainty
Extreme
1-Star Price
$56.34
5-Star Price
$8.94
Economic Moat
Wvyt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CMRX is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.95
Day Range
$0.950.96
52-Week Range
$0.892.40
Bid/Ask
$0.91 / $0.99
Market Cap
$85.73 Mil
Volume/Avg
100,561 / 469,941

Key Statistics

Price/Earnings (Normalized)
21.66
Price/Sales
74.05
Dividend Yield
Dividend Yield (Forward)
Total Yield

Company Profile

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
89

Valuation

Metric
CMRX
Price/Earnings (Normalized)
21.66
Price/Book Value
0.41
Price/Sales
74.05
Price/Cash Flow
Price/Earnings
CMRX

Financial Strength

Metric
CMRX
Quick Ratio
12.54
Current Ratio
12.94
Interest Coverage
Quick Ratio
CMRX

Profitability

Metric
CMRX
Return on Assets (Normalized)
−25.25%
Return on Equity (Normalized)
−27.23%
Return on Invested Capital (Normalized)
−31.58%
Return on Assets
CMRX

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRDhz$450.9 Bil
VRTX
Vertex Pharmaceuticals IncMlhcvg$89.4 Bil
REGN
Regeneron Pharmaceuticals IncHsmfnv$87.3 Bil
SGEN
Seagen Inc Ordinary SharesNmysh$40.4 Bil
MRNA
Moderna IncXygk$29.8 Bil
ARGX
argenx SE ADRPjpq$26.4 Bil
BNTX
BioNTech SE ADRNpxb$23.4 Bil
ALNY
Alnylam Pharmaceuticals IncBjsrdp$20.2 Bil
BMRN
Biomarin Pharmaceutical IncLlpfgn$16.5 Bil
INCY
Incyte CorpSkdcns$11.8 Bil